Effects of insulin and amyloid β 1-42 oligomers on glucose incorporation and mitochondrial function in cultured rat hippocampal neurons

Geriatrics and Gerontology International

Volumn 11, Issue 4, 2011, Pages 517-524

  Miichi, Yoshiaki ^a   Sakurai, Takashi ^a,b   Akisaki, Taichi ^a   Yokono, Koichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

2 deoxyglucose; Adenosine triphosphate; Alzheimer's disease; Insulin; Mitochondria

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN[1-42]; C PEPTIDE; HEXOKINASE; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN NERVE CELL; CELL CULTURE; CELL FUNCTION; GESTATIONAL AGE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HIPPOCAMPUS; IMMUNOBLOTTING; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELLS, CULTURED; GLUCOSE; HIPPOCAMPUS; IMMUNOBLOTTING; INSULIN; LUCIFERASES; MITOCHONDRIA; NEURONS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR;

EID: 80053293769     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2011.00712.x     Document Type: Article

References (38)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766.
2. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004; 430: 631-639.
3. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007; 8: 499-509.
4. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 2008; 14: 45-53.
5. Small GW, Ercoli LM, Silverman DH etal. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2000; 97: 6037-6042.
6. DeLeon MJ, Convit A, Wolf OT etal. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A 2001; 98: 10966-10971.
7. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A 2001; 98: 3334-3339.
8. Mosconi L, DeSanti S, Li J etal. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 2008; 29: 676-692.
9. Bigl M, Brückner MK, Arendt T, Bigl V, Eschrich K. Activities of key glycolytic enzymes in the brains of patients with Alzheimer's disease. J Neural Transm 1999; 106: 499-511.
10. Uemura E, Greenlee HW. Amyloid β-peptide inhibits neuronal glucose uptake by preventing exocytosis. Exp Neurol 2001; 170: 270-276.
11. Prapong T, Buss J, Hsu WH, Heine P, Greenlee HW, Uemura E. Amyloid β-peptide decreases neuronal glucose uptake despite causing increase in GLUT3 mRNA transcription and GLUT3 translocation to the plasma membrane. Exp Neurol 2002; 174: 253-258.
12. Parihar MS, Brewer GJ. Mitoenergetic failure in Alzheimer disease. Am J Physiol Cell Phisiol 2007; 292: C8-C23.
13. Walsh DM, Klyubin I, Fadeeva JV etal. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 418: 535-539.
14. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J Biol Chem 2002; 277: 32046-32053.
15. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64-74.
16. Vanhanen M, Koivisto K, Moilanen L etal. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006; 67: 843-847.
17. Whitmer RA. The epidemiology of adiposity and dementia. Curr Alzheimer Res 2007; 4: 117-122.
18. Zhao WQ, DeFelice FG, Fernandez S etal. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 2008; 22: 246-260.
19. 1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci 2005; 25: 11061-11070.
20. Fusheng Y, Giselle PL, Aynun NB etal. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005; 280: 5892-5901.
21. Brewer GJ, Torricelli JR, Evege EK, Price PJ. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum free medium combination. J Neurosci Res 1993; 35: 567-576.
22. Yamamoto N, Sato T, Kawasaki K, Murosaki S, Yamamoto Y. A nonradioisotope, enzymatic assay for 2-deoxyglucose uptake in L6 skeletal muscle cells cultured in a 96-well microplate. Anal Biochem 2006; 351: 139-145.
23. Sakurai T, Yang B, Takata T, Yokono K. Synaptic adaptation to repeated hypoglycemia depends on the utilization of monocarboxylates in Guinea pig hippocampal slices. Diabetes 2002; 51: 430-438.
24. Wang X, Song X, Takata T, Miichi Y, Yokono K, Sakurai T. Amyloid-β neurotoxicity restricts glucose window for neuronal survival in rat hippocampal slice cultures. Exp Geront 2010; 45: 904-908.
25. McEwena BS, Reagan LP. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol 2004; 490: 13- 24.
26. Zhang W, Yorek M, Pierson CR, Murakawa Y, Breidenbach A, Sima AAF. Human C-peptide dose dependently prevents early neuropathy in the BB/Wor-rat. Int J Exp Diabetes Res 2001; 2: 187-193.
27. Bergersen LH. Is lactate food for neurons? Comparison of monocarboxylater substrate in brain and muscle. Neuroscience 2007; 145: 11-19.
28. Wang XN, Takata T, Sakurai T, Yokono K. Different effects of monocarboxylates on neuronal survival and β-amyloid toxicity. Eur J Neurosci 2007; 26: 2142-2150.
29. Saraiva LM, da Silva GS, Galina A etal. Amyloid-β Triggers the Release of Neuronal Hexokinase 1 from Mitochondria. PLoS ONE 2010; 5: e15230.
30. Reddy PH. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol 2009; 218: 286-292.
31. Sakono M, Zako T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J 2010; 277: 1348-1358.
32. Townsend M, Mehta T, Selkoe DJ. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 2007; 282: 33305-33312.
33. Magdesian MH, Carvalho MM, Mendes FA etal. Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt / beta-catenin signaling. J Biol Chem 2008; 283: 9359-9368.
34. Nimmrich V, Grimm C, Draguhn A etal. Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P / Q-type calcium currents. J Neurosci 2008; 28: 788-797.
35. Brody D, Magnoni S, Schwetye K etal. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 2008; 321: 1221-1224.
36. Hu X, Crick SL, Bu G, Frieden C, Pappu RV, Lee JM. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci U S A 2009; 106: 20324-20329.
37. De Felice FG, Vieira MNN, Bomfim TR etal. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers. Proc Natl Acad Sci U S A 2009; 106: 1971-1976.
38. Watson GS, Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 2004; 490: 97-113.